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A T–C polymorphism in the promoter region of the CYP17 gene has been associated with male and female breast cancer risk as
well as early-onset familial breast cancer. The potential role of this polymorphism was investigated in relation to breast cancer risk in
Icelandic male and female carriers and noncarriers of a BRCA2 mutation. The study population consisted of 39 male and 523 female
breast cancer cases and 309 male and 395 female controls. Of the cases, 15 males and 55 females carried a BRCA2 mutation. We did
not find a significant association between male breast cancer risk and CYP17 genotypes. Among male breast cancer cases, the
frequency of the CC genotype was higher among carriers of the 999del5 mutation (33.3%) than noncarriers (16.7%), although this
difference also did not reach a statistical significance. No association was observed with breast cancer risk among females irrespective
of menopausal status, stage of the disease or BRCA2 status. Our findings do not indicate a role for the CYP17 T–C polymorphism in
female breast cancer, but a role in male carriers of a BRCA2 mutation could not be excluded because of the small sample size.
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Breast cancer is the most common cancer among women in
Iceland, with one out of every 12 women developing breast cancer
in their lifetime (Tulinius et al, 1999). Among men, however,
breast cancer is very rare, only representing about 1% of all breast
cancer cases in Iceland and 0.25% of all malignant tumours in
males (Jonasson et al, 1996).
In Iceland, only one mutation has been found in each of the
BRCA genes, a rare BRCA1 mutation, D1692N (o1% of breast
cancer cases) (Bergthorsson et al, 1998) and a more common
BRCA2 mutation. The BRCA2 mutation is a 5bp deletion in exon
9, 999del5, which leads to an early protein termination (Thorlacius
et al, 1996). Studies have shown that this mutation is found in an
estimated 0.6% of the population. In breast cancer patients, the
carrier frequency is around 8% for females and 40% among males
(Thorlacius et al, 1997). The risk of developing breast cancer varies
greatly between mutation carriers, which indicates the involvement
of genetic and/or environmental modifying factors (Thorlacius
et al, 1998). Possible modifiers include enzymes involved in steroid
hormone biosynthesis, since steroid hormones play an important
role in the development of breast cancer.
The CYP17 gene codes for the cytochrome P450c17a enzyme,
which is involved in the synthesis of androgens and oestrogens.
The 50 untranslated region of the gene contains a T (A1 allele) to C
(A2 allele) polymorphism, 34bp upstream from the initiation of
translation. This base pair change creates an additional Sp1-type
(CCACC) promoter motif, which has been hypothesised to lead
to increased transcriptional activity and enhanced steroid
hormone production (Carey et al, 1994). However, an in vitro
assay was not able to confirm the creation of an Sp1 binding
site (Nedelcheva Kristensen et al, 1999). In spite of that, two
studies have observed elevated levels of sex hormones in serum in
women in association with the C allele (Feigelson et al, 1998;
Haiman et al, 1999).
Several studies have looked at a possible association between the
promoter polymorphism in the CYP17 gene and breast cancer risk
in females. One study found an increased risk of advanced breast
cancer in women carrying a C (A2) allele (Feigelson et al, 1997).
They also observed that the protective effect of older age at
menarche was largely limited to women carrying the TT (A1A1)
genotype. Other studies have followed with mixed results
(Dunning et al, 1998; Helzlsouer et al, 1998; Weston et al, 1998;
Bergman-Jungestrom et al, 1999; Haiman et al, 1999; Huang et al,
1999; Nedelcheva Kristensen et al, 1999; Mitrunen et al, 2000;
Spurdle et al, 2000). The overall findings in these studies suggest
that the CYP17 polymorphism does not have an effect on breast
cancer risk in general, but may modify risk in certain subgroups.
To our knowledge, only one report has stratified risk according to
the BRCA status of the individual. Spurdle et al (2000) reported an
increased risk of early-onset familial breast cancer in association
with the CC genotype. This increase in risk did not seem to apply
to carriers of mutations in either BRCA1 or BRCA2.
One study has been published on the possible role of CYP17
in the development of male breast cancer (Young et al, 1999).
They compared genotype frequencies in 64 breast cancer cases
to 81 controls and found an increased risk of breast cancer in
association with the C (A2) allele (OR¼2.10; 95% CI, 1.04–4.27). Revised 20 December 2002; accepted 10 January 2003
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sTo our knowledge, there have been no published studies on a
potential association between the CYP17 polymorphism and male
breast cancer in BRCA2 carriers.
The current study aimed to investigate the association between
the CYP17 polymorphism and breast cancer risk in Icelandic males
and females. A possible association with the BRCA2 status of males




All male breast cancer cases diagnosed in Iceland from 1955 to
2000 were included in the study, 39 in total. The 29 cases diagnosed
in the time period from 1955–1994 have all been previously
described (Jonasson et al, 1996). All the male breast tumours were
histologically verified and reclassified. The most common
morphological type was infiltrating ductal carcinoma NOS, with
other types constituting less than 20% of the cases. More than 80%
of the infiltrating ductal carcinomas were of grades II and III. The
mean age at diagnosis for the males was 66.2 years (range 42–87
years). DNA extracted from blood was available for 14 of the cases,
but for all other cases DNA was extracted from archival tissue.
DNA was extracted from blood samples using a standard phenol/
chloroform method and from archival tissue using methods
previously described (Wright and Manos, 1990).
For comparison were 309 male controls. Their mean age at the
time of sample collection (1989–1995) was 52 years (range 18–88
years) and all were disease free by the end of the year 2000
according to the Icelandic Cancer Registry. DNA was extracted
from blood, either using a standard phenol/choroform method or
from frozen lymphocytes using a direct proteinase K digestion.
The female cases and controls have been previously described
(Gudmundsdottir et al, 2001). Briefly, a total of 500 Icelandic
females constituted the female breast cancer group, unselected
with respect to family history. They were diagnosed with breast
cancer in the years 1989–1995, with a mean age at diagnosis of
58.5 years (range 28–94 years). Samples were collected at the time
of diagnosis. DNA was extracted from 455 blood samples and 45
tumour samples using a standard phenol/chloroform method.
A total of 23 female breast cancer patients, known to be BRCA2
mutation carriers, were added to the study to increase statistical
power. These carriers come from another ongoing study that
includes all women in Iceland who have been diagnosed with
breast cancer.
The control group consisted of 395 females. Their mean age at
the time of sample collection (1989–1995) was 49 years (range 25–
82 years) and they were disease free by the end of the year 2000
according to the Icelandic Cancer Registry. DNA was extracted
from blood, either using a standard phenol/choroform method or
from frozen lymphocytes using a direct proteinase K digestion.
The study population, both cases and controls, is of a
homogenous ethnical background. All blood samples come from
the Icelandic Cancer Society’s Biological Specimen Bank. Tumour
samples were obtained from the Department of Pathology,
National University Hospital of Iceland. All samples were precoded
and stripped of personal identifiers in accordance with the
standards of the Icelandic Data Protection Authority.
Laboratory analysis
For the CYP17 genotyping, a 459bp fragment was amplified using
primers as previously described (Feigelson et al, 1997). PCR
reactions were carried out in 15ml aliquots containing 25ng of
DNA, 10pmol of each primer, 0.2mM of each dNTP, 1.5mM MgCl2
and 0.36U Dynazyme polymerase (Finnzymes Oy, P.O. Box 148,
FIN-02201, ESP00, Finland). Amplification conditions were 941C
for 3min, followed by 30 cycles of 941C for 30s, 571C for 30s, 721C
for 1min and a final step at 721C for 5min. The PCR products were
digested with 2U of MspA1 (NEB) for 3h at 371C in a final volume
of 25ml and separated on 3% agarose gel (NuSieve 3:1) or on 7.5%
nondenaturant acrylamide gel. A 150bp fragment was amplified
from DNA from archicval samples using primers as previously
described (Young et al, 1999). PCR reactions were carried out as
described above. Amplification conditions were 941C for 3min,
followed by 40 cycles of 941C for 45s, 601C for 45s, 721C for 1min
and a final step at 721C for 5min. PCR products were digested as
described above and separated on 7.5% non-denaturant acryla-
mide gel.
BRCA2 mutation analysis was carried out by exon 9 amplifica-
tion using the forward primer 50-AAAGTCTGAAGAAAAATGA-
TAGATTTA-30 and the reverse primer 50-AAAACCTGTAGTTC-
AACTAAACAG-30 (Tavtigian et al, 1996; Sigurdsson et al, 1997).
The 999del5 mutation carriers were identified by an additional
band, 5bp smaller than the normal fragment, on 6% denaturant
acrylamide gel or by the formation of heteroduplexes between the
two fragments on a 7.5% non-denaturant acrylamide gel.
Statistical analysis
Genotype proportions were compared between groups using the w
2
test, with Yates’ correction, or the Fishers’ exact test when
appropriate. Tests for the Hardy–Weinberg equilibrium were
conducted by comparing observed and expected genotype
frequencies using a w
2 test. All analyses were performed using
the statistical software package STATA 6.0 (STATA Corporation,
College Station, TX, USA).
RESULTS
The distribution of the CYP17 genotypes was compared between
the male breast cancer cases and 309 male controls (Table 1). No
significant difference in genotype frequencies was observed
between the two groups, although the frequency of the CC
genotype was somewhat higher among cases (23.1%) than controls
(14.9%) (P¼0.32). No significant departures from the Hardy–
Weinberg equilibrium were observed for the CYP17 genotypes
among controls (P¼0.66) or cases (P¼0.90).
In all, 15 of the male cases were positive for the 999del5
mutation in the BRCA2 gene or 38.5%. The male breast cancer
cases were divided into two groups according to their BRCA2
status and CYP17 genotype frequencies compared between them
(Table 1). The CC genotype was more frequent among the carriers
(33.3%) as compared to the noncarriers (16.7%), although this was
not statistically significant (P¼0.40).
Possible association of the CYP17 polymorphism with female
breast cancer was also investigated by comparing the genotype
frequencies between 500 breast cancer cases and 395 female
Table 1 Associations between CYP17 genotype and male breast cancer
according to BRCA2 status
TT TC CC
All
Cases, n (%) 12 (30.8) 18 (46.1) 9 (23.1)
Controls, n (%) 103 (33.3) 160 (51.8) 46 (14.9)
OR (95% Cl) 1.0 0.97 (0.45–2.09) 1.68 (0.66–4.26)
BRCA2 status of cases
999del5, n (%) 4 (26.7) 6 (40.0) 5 (33.3)
wt, n (%) 8 (33.3) 12 (50.0) 4 (16.7)
OR (95% Cl) 1.0 1.00 (0.21–4.71) 2.50 (0.42–14.84)
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scontrols (Table 2). No significant differences in genotype
frequencies were observed between the two groups. The results
did not change when the case group was divided into cases
diagnosed before the age of 45 or after the age of 55 (results not
shown). No statistically significant departures from Hardy–
Weinberg equilibrium were observed for the CYP17 genotypes
among controls (P¼0.61) or cases (P¼0.63).
Of the 500 cases, 363 were analysed for BRCA2 status. Of them,
32 (8.8%) were carriers of the 999del5 mutation. To increase the
power of the analysis, 23 BRCA2 carriers diagnosed with breast
cancer were added to the group. The CYP17 genotype frequencies
were compared between the 55 carriers and 331 noncarriers, but
no difference was observed between the two groups (Table 2).
Information about the stage of the disease was available for 481
patients out of 500 (Table 3). Five of those were classified as stage 0
and were not included in this part of the study. No association was
observed between the CYP17 polymorphism and the stage of the
disease among female breast cancer patients.
DISCUSSION
To our knowledge, this is the first study to look for possible
modifying effects on breast cancer risk among male BRCA2
mutation carriers. Young et al (1999) have reported a significant
association of the C allele with increased risk of male breast cancer
in a small study of 64 cases and 84 controls. Inevitably, the cases in
this study are also few, but to increase the power of the study we
used a larger control group of 309 individuals, giving 90% power to
detect an ORX1.5 for carriers of at least one C allele, which is
enough power to detect the increased risk of 2.1 reported by Young
et al (1999). Despite that, our results do not indicate an association
between the CYP17 polymorphism and risk of male breast cancer.
We observed a slight increase in frequency of the CC genotype
among the cases (23.1%) compared to controls (14.9%), but the
difference did not reach statistical significance. It is quite
interesting to note that the observed increase in frequency seemed
mainly to be attributed to BRCA2 mutation status, as the CC
genotype frequency was 33.3% among carriers but 16.7% among
noncarriers, but again the difference was not statistically
significant.
In females, we did not find any significant association between
the CYP17 polymorphism and breast cancer risk, irrespective of
menopausal status or stage of the disease, which is in agreement
with most studies published so far (Dunning et al, 1998; Helzlsouer
et al, 1998; Weston et al, 1998; Haiman et al, 1999; Nedelcheva
Kristensen et al, 1999). In the first study published on this matter,
Feigelson et al (1997) reported an increased risk of advanced
breast cancer in women carrying a C allele (OR¼2.5, 1.07–5.94).
We were unable to confirm those results, despite having 90%
power to detect ORX1.5 for carriers of at least one C allele when
comparing genotype frequencies between controls and cases with
stage III+IV of the disease. To our knowledge, the only other paper
showing an association with the stage of the disease is that of
Mitrunen et al (2000), who found a decreased risk of advanced
breast cancer in association with the C allele among premeno-
pausal women (OR¼0.58, 0.31–1.07). Our results suggest that the
T–C polymorphism in the CYP17 gene does not contribute to
breast cancer risk in females overall or to the stage of the disease.
We were also interested to see whether the CYP17 polymorph-
ism could act as a modifier of breast cancer risk in female BRCA2
mutation carriers. According to our results this does not seem to
be the case, which is in agreement with the results of Spurdle et al
(2000).
It is of special interest to examine possible modifying effects of
different polymorphism on cancer risk in BRCA2 carriers in the
Icelandic population. The reason is that only one BRCA2 mutation
has been found and it shows very varied penetrance and
expression (Thorlacius et al, 1997). It could be that an increase
in oestrogen levels, possibly associated with the C allele of the
CYP17 gene, could increase the risk of breast cancer in BRCA2
mutation carriers. BRCA2 mutated cells are not as efficient in
repairing DNA damage as normal cells (Patel et al, 1998) and thus
increased oestrogen levels could augment the mutation frequency
even further. It would be interesting to investigate whether
polymorphisms in other oestrogen metabolism genes would
influence breast cancer risk in BRCA2 carriers.
In conclusion, our results do not suggest a major role for the
CYP17 promoter polymorphism in breast cancer risk in general
among males or females, but we were not able to exclude an
association with breast cancer risk in male BRCA2 carriers because
of the small sample size.
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